Clinical Study Results
Research Sponsor: AstraZeneca AB
Drug Studied: Acalabrutinib
Study Purpose: This study was done to learn more about
how acalabrutinib acts in the blood
and about its safety in patients with
COVID-19 who need hospital care
Protocol Number: D822FC00005
Thank you
Thank you for taking part in the clinical study for the study drug acalabrutinib.
AstraZeneca AB sponsored this study and believes it is important to share the
results. An independent non-profit organization called CISCRP helped prepare this
summary of the study results for you.
If you participated in the study and have questions about the results, please speak
with the study doctor or staff at your study site.
1